Dallas, Texas 01/21/2014 (FINANCIALSTRENDS) – BioDelivery Sciences International, Inc.(NASDAQ:BDSI) is a pharmaceutical company which utilizes licensed as well as proprietary drug delivery technologies which allows the company to develop besides commercialize new formulations for most of the known therapeutics.
BioDelivery Sciences International, Inc.(NASDAQ:BDSI) has a market cap of $246.93 million and volume of 773,828. The 52 week high for the company was $6.50 and 52 week low was $3.52. The EPS stood at -1.25.
BioDelivery Sciences International, Inc.(NASDAQ:BDSI) latest drug before the FDA for approval is Bunavail. The company expects the approval for this drug will be available by the end of June 2014. The company expects to see the drug sell very well in US. Conservative estimates are currently at $250 million.
BioDelivery Sciences International, Inc.(NASDAQ:BDSI) has since appointed a new Vice president of Sales in December last – David Acheson. His appointment has been in the wake of the likely launch of Bunavil. The company expects to see quick action and wants the new VP to focus on developing and establishing the market processes to manage the product. The company also expects the Phase 3 trial of another of its drugs- Clonidine Topical Gel to be completed by the end of the first quarter of 2014.
BioDelivery Sciences International, Inc.(NASDAQ:BDSI) is positive about the results of this gel application before the FDA, following talks.
The company has a long history in the development of pharmaceutical products which are aimed at managing pain. These drugs are also known to be excellent against cancerous post-operative support. The key change that has ensured these to be new formulation changes for known therapies is the use of Bio Erodible MucoAdhesive or BEMA drugs. These drugs deliver technology as well as polymer film application which will allow in the application to the buccal mucosa. One of the noted products is Onsolis.